Tecemotide (** L-BLP25 (investigational name); no approved brand names as it has not received regulatory approval. **)

Description

Tecemotide (also known as L-BLP25) is an investigational medication being studied for its potential use in colorectal cancer, specifically rectal cancer. It is currently in Phase 2 clinical trials. The goal of these trials is to see if tecemotide can stimulate the body's own immune system to fight cancer cells. It works by targeting a protein called MUC1, which is found on the surface of many cancer cells, including those in colorectal cancer. By targeting MUC1, tecemotide aims to trigger an immune response that could help the body recognize and attack the tumor. It is being investigated as a potential treatment, often in combination with other therapies like chemotherapy (e.g., cyclophosphamide), before or during standard treatment for rectal cancer.

Mechanism of Action

Tecemotide is designed to activate the immune system against cancer. It targets MUC1, a protein often found in high amounts on the surface of colorectal cancer cells. By stimulating an immune response against MUC1, the drug aims to help the body's immune cells (like T-cells) recognize and destroy cancer cells that express this protein. This approach is a form of cancer immunotherapy, attempting to harness the body's natural defenses to fight the disease.

Side Effects

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials